Cardiovascular Catch-Up: TAVR Withstands Delta Virus So Far; Stereotaxis Robot Succeeds In Trial
Executive Summary
The impact of the Delta variant of COVID-19 on procedure volumes remains a major concern for transcatheter valve makers, Abbott launches a new PFO closure device, and more highlights from the cardiovascular technology market in early October.
You may also be interested in...
Minute Insight: HeartFlow Drops SPAC Plan; Names New Leadership
John Farquhar, who served as HeartFlow’s COO since August 2021, will now lead the cardiac imaging company as CEO. The move comes just weeks after HeartFlow terminated plans to go public through a merger with a special purpose acquisition company.
Digital Health Roundup: Digital Therapeutics Push Ahead On Standards, Coverage; FDA’s Software Guidance
In this roundup feature focusing on developments in digital health, we highlight the key news and announcements from October.
Hospital Staffing Shortages Could Impede Recovery Of Procedure Volumes
Even as COVID-19 hospitalization rates are declining, expected staff shortages could force more hospitals to postpone surgeries and interventions in the coming months.